Evidence map›Paper›PMID 39544544›Full record

ArticleCureus2024

Thoracic Re-irradiation With Definitive External Beam Radiation Therapy Using Intensity Modulated Radiation Therapy: A Case Report.

Unta Yamamori, Yukihisa Tamaki, Masafumi Uno, Atsushi Ue, Yoko Sonoyama

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Unta YamamoriRadiation Oncology, Shimane University Faculty of Medicine, Izumo, JPN.
Yukihisa TamakiRadiation Oncology, Shimane University Faculty of Medicine, Izumo, JPN.
Masafumi UnoRadiation Oncology, Shimane University Faculty of Medicine, Izumo, JPN.
Atsushi UeRadiation Oncology, Shimane University Faculty of Medicine, Izumo, JPN.
Yoko SonoyamaRadiation Oncology, Shimane University Faculty of Medicine, Izumo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thoracic re-irradiation has a high risk of severe adverse events, and re-irradiation with curative intent has rarely been performed. However, in recent years, with the introduction of intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy, it has become possible to deliver high doses to the target lesions while minimizing the doses to surrounding tissues. The patient in this case had a history of definitive radiation therapy for esophageal cancer. The patient developed new lung cancer, which was treated by re-irradiation. We created a radiation treatment plan using IMRT. This allowed us to reduce the dose to organs at risk and deliver a higher dose to the cancer, increasing the potential for cure. The patient has not experienced any severe late adverse events as of three years and six months after treatment. Additionally, the treatment has been sufficiently effective, and the patient remains recurrence-free. To confirm the feasibility of the IMRT plan, we also created a radiation treatment plan using three-dimensional conformal radiation therapy (3D-CRT) and compared it with the IMRT plan. Compared with 3D-CRT, the IMRT plan was able to reduce the dose to organs at risk and meet the dose constraints indicated in multiple studies. The possibility of adverse events such as bronchial hemorrhage, esophageal hemorrhage, bronchial fistula, radiation pneumonitis, esophageal fistula, and pericarditis was significantly reduced.

Indexed as

intensity modulated radiation therapythoraciclung cancerradiation therapyre-irradiationtolerated dose

Identifiers

PMID39544544
PMCPMC11562875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.